← Back to Search

Procedure

Menghini-type needle for Sarcoidosis

N/A

Recruiting

Led By Kazuhiro Yasufuku

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

Study Summary

This trial wants to see if using Franseen-type needles for sample collection can help diagnose sarcoidosis better than the conventional Menghini-type needle.

Who is the study for?

This trial is for individuals with sarcoidosis, a condition where tiny clumps of inflammatory cells grow in different parts of the body. Participants should be suitable candidates for a procedure called EBUS-TBNA, which collects tissue samples from the lungs.Check my eligibility

What is being tested?

The study is testing two types of needles used in EBUS-TBNA: Franseen-type and Menghini-type. It aims to determine if the Franseen needle provides better quality samples for diagnosing sarcoidosis compared to the conventional Menghini needle.See study design

What are the potential side effects?

EBUS-TBNA may cause coughing, bleeding at puncture sites, infection risk, shortness of breath or discomfort during and after the procedure. The side effects can vary based on individual patient factors.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To examine whether sample collection with Franseen-type needles are effective for the diagnosis of sarcoidosis, as defined by improved sample quality for pathological diagnosis compared to the conventional Menghini-type needle.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Menghini-type needleExperimental Treatment1 Intervention

the standard needle type

Group II: Franseen-type needlesActive Control1 Intervention

the active comparator arm

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,476 Previous Clinical Trials

485,052 Total Patients Enrolled

1 Trials studying Sarcoidosis

60 Patients Enrolled for Sarcoidosis

Kazuhiro YasufukuPrincipal InvestigatorUHN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available openings for patients to participate in this study?

"Indeed, the details on clinicaltrials.gov confirm that this ongoing clinical trial is actively seeking suitable candidates. The initial posting date was August 18th, 2023 and the most recent update occurred on January 12th, 2024. The trial aims to recruit a total of 128 participants at a single location."

Answered by AI

What is the current number of individuals being admitted into this research investigation?

"Indeed, the details available on clinicaltrials.gov confirm that this study is currently accepting applications. The trial was initially posted on August 18th, 2023 and recently updated on January 12th, 2024. A total of 128 participants will be enrolled at a single location for this research endeavor."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Comparing Menghini-type Needle and Franseen-type Needle in EBUS-TBNA for Sarcoidosis

Kazuhiro Yasufuku 2023. "Comparing Menghini-type Needle and Franseen-type Needle in EBUS-TBNA for Sarcoidosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06220526.

All > Stronger Than Sarcoidosis > Sarcoidosis